Publications
Most Recent
Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma
In summary, this study defined state change and lineage selection during melanoma treatment with spatiotemporal resolution, elucidating how choice and timing of therapeutic agents will impact the ability to eradicate resistant clones.
Rubinstein JC, Domanskyi S, Sheridan TB, et.al, Cancer Research, March 2025
PDX Data Commons and Coordinating Center
2025
Multicenter Histology Image Integration and Multiscale Deep Learning for Machine Learning-Enabled Pediatric Sarcoma Classification, Thiesen A, Domanskyi S, Foroughi Pour A, Zhang J, Sheridan TB, Neuhauser SB, Stetson A, Dannheim K, Cameron DB, Ahn S, Wu H, Christison Lagay ER, Bult CJ, Chuang JH, Rubinstein JC, medRxiv [Preprint]. 2025 Jun 11:2025.06.10.25328700. doi: 10.1101/2025.06.10.25328700. PMID: 40585079
Spatiotemporal Profiling Defines Persistence and Resistance Dynamics during Targeted Treatment of Melanoma, Rubinstein JC, Domanskyi S, Sheridan TB, Sanderson B, Park S, Kaster J, Li H, Anczukow O, Herlyn M, Chuang JH, Cancer Res. 2025 Mar 3;85(5):987-1002. doi: 10.1158/0008-5472. CAN-24-0690. PMID: 39700408
2024
A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis, White, BS, Woo, X, Koc, S, Sheridan, T, Neuhauser, SB, Wang, S, Evrard, YA, Landua, JD, Mashl, RJ, Davies, SR, Fang, B, Raso, MG, Evans, KW, Bailey, MH, Chen, Y, Xiao, M, Rubinstein, J, Pour, AF, Dobrolecki, LE, Fujita, M, Fujimoto, J, Xiao, G, Fields, RC, Mudd, JL, Xu, X, Hollingshead, MG, Jiwani, S, PDXNet Consortium, Davis-Dusenbery, B, Wallace, TA, Moscow, JA, Doroshow, JH, Mitsiades, N, Kaochar, SK, Pan, CX, Chen Jr, MS, Carvajal-Carmona, LG, Welm, AL, Welm, BE, Govindan, R, Li, S, Davies, MA, Roth, JA, Meric-Bernstam, F, Xie, Y, Herlyn, M, Ding, L, Lewis, MT Bult, CJ, Dean II, DA, Chuang, JH, Cancer Research, 2024 Jul 2;84(13):2060-2072. PMID: 39082680, doi: 10.1158/0008-5472.CAN-23-1349.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: a National Cancer Institute Patient-Derived Xenograft Development and Trial Center Research Network (PDXNet) Report, Meric-Bernstam, F, Lloyd, MW, Koc, S, Evrard, Y, Dean II, DA, McShane, LM, Lewis, MT, Evans, K, Li, D, Rubinstein, L, Welm, AL, Srivastava, A, Grover, JW, Ha, M, MJ-H, Chen, H, Huang, X, Wang, J, Roth, J, Welm, BE, Govinden, R, Ding, L, Kaochar, S, Mitsiades, N, Carvajal-Carmona, PDXNET Consortium, Herylyn, M, Davies, MA, Doroshow, JH, Chuang, JH, Moscow, JA, Mol Cancer Ther, 2024 Apr 19;23(7):924–938. PMID: 38641411, doi: 10.1158/1535-7163.MCT-23-0471.
Development, and application of genetic ancestry reconstruction methods to study the diversity of patient-derived models in the NCI PDXNet Consortium, Sanderson, BJ, Lott, P, Chiu, K, Quino, JE, Vang, AP, Lloyd, ML, Srivastava, A, PDXNet Consortium, Chuang, JH, Carvajal-Carmona, LG, Cancer Res Commun., 2024 Aug 1;4(8):2147-2152. PMID: 39056190, doi: 10.1158/2767-9764.CRC-23-0417.
Nextflow pipeline for Visium and H&E data from patient-derived xenograft samples, Domanskyi S, Srivastava A, Kaster J, Li H, Herlyn M, Rubinstein JC, Chuang JH, Cell Rep Methods, 2024 May 20;4(5):100759. doi: 10.1016/j.crmeth.2024.100759. Epub 2024 Apr 15. PMID: 38626768
STRprofiler: efficient comparisons of short tandem repeat profiles for biomedical model authentication, Andrews JM, Lloyd MW, Neuhauser SB, Bundy M, Jocoy EL, Airhart SD, Bult CJ, Evrard YA, Chuang JH, Baker S, Bioinformatics, 2024 Nov 28;40(12):btae713. doi: 10.1093/bioinformatics/btae713. PMID: 39589865
2022
Genetically diverse mouse platform to xenograft cancer cells, Sargent JK, Warner MA, Low BE, Schott WH, Hoffert T, Coleman D, Woo XY, Sheridan T, Erattupuzha S, Henrich PP, Philip VM, Chuang JH, Wiles MV, Hasham MG, Dis Model Mech, 2022 Sep 1;15(9):dmm049457. doi: 10.1242/dmm.049457. Epub 2022 Aug 29. PMID: 36037073
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery, Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H; PDXNet Consortium; Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA 2nd, Chuang JH, NAR Cancer, 2022 Apr 22;4(2):zcac014. doi: 10.1093/narcan/zcac014. eCollection 2022 Jun. PMID: 35475145
2021
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium, Nat Genetics, 2021 Jan;53(1):86-99. doi: 10.1038/s41588-020-00750-6. Epub 2021 Jan 7. PMID: 33414553
2020
BCO App: tools for generating BioCompute Objects from next-generation sequencing workflows and computations, Xiao N, Koc S, Roberson D, Brooks P, Ray M, Dean D.F1000Res. 2020 Sep 16;9:1144. doi: 10.12688/f1000research.25902.1. eCollection 2020.PMID: 33299553
Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis, Evrard YA, Srivastava A, Randjelovic J, Doroshow JH, Dean DA 2nd, Morris JS, Chuang JH; NCI PDXNet Consortium, Cancer Research, 2020 Jun 1;80(11):2286-2297. doi: 10.1158/0008-5472.CAN-19-3101. Epub 2020 Mar 9. PMID: 32152150
Treating Cancer as an Invasive Species, Noorbakhsh J, Zhao ZM, Russell JC, Chuang JH.Mol Cancer Res. 2020 Jan;18(1):20-26. doi: 10.1158/1541-7786.MCR-19-0262. Epub 2019 Sep 16. PMID: 31527151
2019
CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer, Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, Chuang JH, Yuan Y, BMC Cancer, 2019 Jan 21;19(1):96. doi: 10.1186/s12885-019-5290-4. PMID: 30665374
2018
Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments, Cho SY, Sung CO, Chae J, Lee J, Na D, Kang W, Kang J, Min S, Lee A, Kwak E, Kim J, Choi B, Kim H, Chuang JH, Pak HK, Park CS, Park S, Ko YH, Lee D, Roh J, Cho MS, Park S, Ju YS, Suh YS, Kong SH, Lee HJ, Keck J, Banchereau J, Liu ET, Kim WH, Park H, Yang HK, Kim JI, Lee C, Blood, 2018 Apr 26;131(17):1931-1941. doi: 10.1182/blood-2017-07-797209. Epub 2018 Feb 23. PMID: 29475961
Distribution-based measures of tumor heterogeneity are sensitive to mutation calling and lack strong clinical predictive power, Noorbakhsh J, Kim H, Namburi S, Chuang JH.Sci Rep. 2018 Jul 30;8(1):11445. doi: 10.1038/s41598-018-29154-7.PMID: 30061557
High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts, Kim H, Kumar P, Menghi F, Noorbakhsh J, Cerveira E, Ryan M, Zhu Q, Ananda G, George J, Chen HC, Mockus S, Zhang C, Yang Y, Keck J, Karuturi RKM, Bult CJ, Lee C, Liu ET, Chuang JH.Sci Rep. 2018 Dec 18;8(1):17937. doi: 10.1038/s41598-018-36184-8.PMID: 30560892
PDX Development and Trial Centers
The following 52 publications were generated in the first PDXNet funding cycle.
2022
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology, Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL. Nat Cancer, 2022 Feb;3(2):232-250. doi: 10.1038/s43018-022-00337-6. Epub 2022 Feb 24. PMID: 35221336
2021
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer, Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan M, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F, Clin Cancer Res, 2021; Jan 07. PMID: 33414137
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment, Sun, H., Cao, S., Mashl, R.J. et al. Nat Commun 12, 5086 (2021). https://doi.org/10.1038/s41467-021-25177-3
Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells, Miranda MA, Marcato PD, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni SK, Bentley MVLB, Amaral R, Pan CX, Singh M, Mater Sci Eng C Mater Biol Appl, 2021; 119:111460
Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis, Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M, Cancer Lett. 2021 Feb 4:S0304-3835(21)00061-6. doi: 10.1016/j.canlet.2021.01.029. Epub ahead of print. PMID: 33549708.
Emerging strategies to treat rare and intractable subtypes of melanoma, Alicea GM, Rebecca VW, Pigment Cell Melanoma Res, 2021; 34:44–58. PMID: 32274887; PMCID: PMC7544642
Elevated NSD3 Histone Methylation Activity Drives Squamous Cell Lung Cancer, Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Chua K, Roth JA, Minna JD, Shao NY, Jaremko L, Mazur PK, Gozani O, Nature, 2021; 590(7846):504–508. PMID: 33536620
Hormonal Modulation of ESR1 Mutant Metastasis, Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Ando S, Fuqua SAW, Oncogene 2021 Feb; 40(5):997-101, Epub 2020 Dec 15, doi: 10.1038/s41388-020-01563-x
Moving Pan-Cancer Studies from Basic Research Toward the Clinic, Chen, F, Wendl, MC, Wyczalkowski, M, Bailey, MH, Li, Y, Ding, L, Nat Cancer, 2021 Sep;2(9):879-890. Epub 2021 Sep 16. doi: 10.1038/s43018-021-00250-4.
PAF Remodels the DREAM Complex to Bypass Cell Quiescence and Promote Lung Tumorigenesis, Kim MJ, Cervantes C, Jung YS, Zhang X, Zhang, J, Lee SH, Jun S, Litovchick L, Wang W, Chen J, Fang B, Park JI, Molecular Cell, 2021 Apr 15;81(8):1698-1714.e6, Epub 2021 Feb 23. doi: 10.1016/j.molcel.2021.02.001.
Therapeutic Targeting of Nemo-Like Kinase in Primary and Acquired Endocrine-Resistant Breast Cancer, Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea M, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS, Clin Cancer Res, 2021 May 1;27(9):2648-2662, Epub 2021 Feb 4, doi: 10.1158/1078-0432.CCR-20-2961.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy, Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M, Nat Commun, 2021; 12:346. doi: 10.1038/s41467-020-20600-7, PMID: 33436641; PMCID: PMC7804257
2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers, Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X and Dmitrovsky E, Mol Cancer Ther 2020; doi: 10.1158/1535-7163.MCT-19-0987, PMID: 33277443
A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models, Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX, Cancers (Basel), 2020; 12:1304, doi: 10.3390/cancers12051304, PMID: 32455634
Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer, Bulle A, Lim KH, Signal Transduct Target Ther, 2020, 5:249, doi: 10.1038/s41392-020-00341-1, PMID: 33122631; PMCID: PMC7596088.
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer, Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX, Cancer Immunol Immunother, 2020; 69:2305–2317, Epub 2020 Jun 6, doi: 10.1007/s00262-020-02609-5.
Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer, Liu X, Olszewski K, Zhang Y, Lim EW, Shi J, Zhang X, Zhang J, Lee H, Koppula P, Lei G, Zhuang L, You MJ, Fang B, Li W, Metallo CM, Poyurovsky MV, Gan B, Nat Cell Biol, 2020; 22:476–486, doi: 10.1038/s41556-020-0496-x, Epub 2020 Mar 30, PMID: 32231310; PMCID: PMC7194135
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion, Jiang H, Liu X, Knolhoff BL, Hegde S, Lee KB, Jiang H, Fields RC, Pachter JA et al, Gut 2020, 69:122-132, Epub 2019 May 10, doi: 10.1136/gutjnl-2018-317424, PMID: 31076405; PMCID: PMC7167297
Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP, Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song Y, J Med Chem, 2020; 63(9):4716–4731, Epub 2020 Apr 21, doi: 10.1021/acs.jmedchem.9b02164, PMID: 32314924; PMCID: PMC7340344
Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients, Kaochar S, Mitsiades N, Ann Oncol. 2020 Mar; 31(3):323-325, doi: 10.1016/j.annonc.2020.01.009, PMID: 32067673
Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization, Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B, Am J Cancer Res, 2020; 9:1201–1211. PMID: 31285952; PMCID: PMC6610060
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma, Das I, Chen H, Maddalo G, Tuominen R, Rebecca VW, Herlyn M, Hansson J, Davies MA, Egyházi Brage S, Cell Death Dis, 2020; 11:882, doi: 10.1038/s41419-020-03097-2, PMID: 33082316; PMCID: PMC7576205
Is it safe to stop Anti-PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response? Davies MA, J Clin Oncol., 2020; 38:1645-1647, Epub 2020 Feb 25, doi: 10.1200/JCO.20.00136, PMID: 32097093; PMCID: PMC7238487
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations, Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B, Am J Cancer Res, 2020; 10:4464–4475. PMID: 33415011; PMCID: PMC7783771
Landscape analysis of adjacent gene rearrangements reveals BCL2L14–ETV6 gene fusions in more aggressive triple-negative breast cancer, Lee S, Hu Y, Loo SK, Tan Y, Bhargava R, Lewis MT, Wang XS, Proc Natl Acad Sci USA, 2020; 117(18):9912–9921. DOI: 10.1073/pnas.1921333117. PMID: 32321829
Microscaled proteogenomic methods for precision oncology, Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, Mutch D, Watson MA, Ma C, Ademuyiwa FO, Rimawi MF, Schiff R, Hoog J, Jacobs S, Malovannaya A, Hyslop T, Clauser KR, Mani DR, Perou CM, Miles G, Zhang B, Gillette MA, Carr SA, Ellis MJ, Nat Commun, 2020; 11(1):532, doi: 10.1038/s41467-020-14381-2, PMID: 31988290; PMCID: PMC6985126
Neurofibromin Is an Estrogen Receptor-alpha Transcriptional Co-repressor in Breast Cancer, Zheng, Z. et al, Cancer Cell, 2020 Mar 16; 37(3):387-402.e7, Epub 2020 Mar 5, doi: 10.1016/j.ccell.2020.02.003.
Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical (18)F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts, Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Primeau T, Luo J, Li S et al., J Nucl Med, 2020; 61:842–849, Epub 2019 Nov 22, doi: 10.2967/jnumed.119.234286, PMID: 31757841; PMCID: PMC7262224
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models, Guo Z, Primeau T, Luo J, Zhang C, Sun H, Hoog J, Gao F, Huang S et al, Cancers (Basel) 2020, 12, doi: 10.3390/cancers12123857, PMID: 33371187; PMCID: PMC7765949.
SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth, Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez Gomez JM, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan-Hersh E, Livneh I, Scortegagna M, Brown K, Larsson O, Topisirovic I, Wolfenson H, Herlyn M, Flaherty K, Dummer R, Ronai ZA, Mol Cancer Res, 2020; 18:1560–1573, Epub 2020 Jun 22, doi: 10.1158/1541-7786.MCR-20-0291, PMID: 3257198; PMCID: PMC7541784
Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis, Evrard YA, Srivastava A, Randjelovic J, Doroshow JH, Dean DA 2nd, Morris JS, Chuang JH; NCI PDXNet Consortium, Cancer Res, 2020; 80:2286–2297, Epub 2020 Mar 9, doi: 10.1158/0008-5472.CAN-19-3101, PMID: 32152150; PMCID: PMC7272270
2019
A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors, Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ, Clin Cancer Res, 2019; 25:6852–6867, Epub 2019 Aug 2, doi: 10.1158/1078-0432.CCR-19-0253, PMID: 31375515; PMCID: PMC6906212
A melanoma patient-derived xenograft model, Xiao M, Rebecca VW, Herlyn M, J Vis Exp, 2019; (147), doi: 10.3791/59508, PMID: 31157772; PMCID: PMC6986799
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses, Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. Cancer Immunol Res. 7:1267-1279;2019, Epub 2019 Jun 11, doi: 10.1158/2326-6066.CIR-18-0874, PMCID: PMC7213862
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma, Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, Maurer-Granofszky M, Roka F, Penz T, Bock C, Zhang G, Herlyn M, Glatz K, Läubli H, Mertz KD, Petzelbauer P, Wiesner T, Hartl M, Pickl WF, Somasundaram R, Steinberger P, Wagner SN, Nat Commun, 2019; 10:4186, doi: 10.1038/s41467-019-12160-2, PMID: 31519915; PMCID: PMC674445
BRAF targeting sensitizes resistant melanoma to cytotoxic T cells, Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards A, Moberg V, Pilon-Thomas S, Schell M, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI, Clin Cancer Res, 2019; 25:2783–2794, Epub 2019 Feb 14, doi: 10.1158/1078-0432.CCR-18-2725, PMID: 30765391; PMCID: PMC6497575
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity, Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E, Cancer Res, 2019; 79(16):4258–4270. doi: 10.1158/0008-5472.CAN-18-3835. PMID: 31213465
Fidelity of a PDX-CR model for bladder cancer, Mondal AM, Ma A, Li G, Krawczyk E, Lu J, Schlegel R, Pan C, Liu X, Biochem Biophys Res Commun, 2019; 517:49, Epub 2019 Jul 11, doi: 10.1016/j.bbrc.2019.06.165
Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization, Baity M, Wang L, Correa AM, Zhang X, Zhang R, Pataer A, Wu S, Meng QH, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Zhao M, Gu J, Fang B, Am J Cancer Res, 2019; 9:1201–1211. PMID: 31285952; PMCID: PMC6610060
Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis, Yan, X.; Zhang, X.; Wang, L.; Zhang, R.; Pu, X.; Wu, S.; Li, L.; Tong, P.; Wang, J.; Meng, Q.; Jensen, V. B.; Girard, L.; Minna, J. D.; Roth, J. A.; Swisher, S. G.; Heymach, J. V.; Fang, B. Cancer Res 2019, 79, 125-132, Epub 2018 Nov 6, doi: 10.1158/0008-5472.CAN-18-1938, PMID: 30401714. PMCID: PMC7293542
Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice, Martin KA, Hum NR, Sebastian A, He W, Siddiqui S, Ghosh PM, Pan C, de Vere White R, Loots GG. Intl J Mol Science. 2019 20: pii: E4983, doi: 10.3390/ijms20204983
Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis, Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM, EMBO Mol Med, 2019; 11:e9960, doi: 10.15252/emmm.201809960, PMID: 31040125; PMCID: PMC6505578
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity, Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3. PMID: 31588020. PMCID: PMC: PMC6944069.
Suppression of p16 induces mTORC1-mediated nucleotide metabolic reprogramming, Buj R, Chen CW, Dahl ES, Leon KE, Kuskovsky R, Maglakelidze N, Navaratnarajah M, Zhang G, Doan MT, Jiang H, Zaleski M, Kutzler L, Lacko H, Lu Y, Mills GB, Gowda R, Robertson GP, Warrick JI, Herlyn M, Imamura Y, Kimball SR, DeGraff DJ, Snyder NW, Aird KM, Cell Rep, 2019; 28:1971–1980, doi: 10.1016/j.celrep.2019.07.084, PMID: 31433975; PMCID: PMC6716532
Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis, Evrard YA, Srivastava A, Randjelovic J, Doroshow JH, Dean DA 2nd, Morris JS, Chuang JH; NCI PDXNet Consortium, Cancer Res, 2019; 80:2286–2297, Epub 2020 Mar 9, doi: 10.1158/0008-5472.CAN-19-3101, PMID: 32152150; PMCID: PMC7272270
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer, Owusu-Brackett, N., Evans, K. W., Akcakanat, A., Yuca, E., Tapia, C., Rizvi, Y. Q., Dumbrava, E. I., Janku, F., & Meric-Bernstam, F. Oncotarget, 2019; 10(49), 5011–5019, doi: 10.18632/oncotarget.27082, PMID: 31489111. PMCID: PMC6707945.
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models, Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E, Mol Cancer Res, 2019; 17(10):2063–2076. doi: 10.1158/1541-7786.MCR-19-0040. PMID: 31320385
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice, Chen Y, Zhang R, Wang L, Correa AM, Pataer A, Xu Y, Zhang X, Ren C, Wu S, Meng QH, Fujimoto J, Jensen VB, Antonoff MB, Hofstetter WL, Mehran RJ, Pisimisis G, Rice DC, Sepesi B, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Heymach JV, Fang B, Cancer, 2019; 125:3738–3748, Epub 2019 Jul 9, doi: 10.1002/cncr.32366, PMID: 31287557; PMCID: PMC7294643
2018
Melanoma in 2017: Moving treatments earlier to move further forwards, Davies MA, Flaherty KT, Nat Rev Clin Oncol, 2018; 15:75–76, Epub 2017 Nov 28, doi: 10.1038/nrclinonc.2017.183, PMID: 29182162; PMCID: PMC7436336
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer, Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B, J Transl Med, 2018; 16:328, doi: 10.1186/s12967-018-1704-3, PMID: 30477533; PMCID: PMC6260563
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma, Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E, Nat Med, 2018; 24:1545–1549, Epub 2018 Aug 20, doi: 10.1038/s41591-018-0157-9, PMID: 30127394; PMCID: PMC6693632
Targeting Resistance to Targeted Therapies: Combating a Resilient Foe, Devarakonda S, Govindan R, Clin Cancer Res, 2018; 24:6112–6114, Epub 2018 Oct 23, doi: 10.1158/1078-0432.CCR-18-3178, PMID: 30352903; PMCID: PMC6295273